Tokyo, Japan—Tosoh Corporation has announced that it will be increasing the production capacity of its TOYOPEARL liquid chromatography separation and purification media at its Nanyo Complex, in Shunan, Yamaguchi Prefecture. The nearly 50% production capacity increase is in response to growing global demand for purification media from the antibody drug manufacturing industry.
At a cost of approximately ¥5 billion (about 42 million €), the Nanyo Complex’s TOYOPEARL production facilities are being expanded. Construction began in October 2016 and is slated for completion in August 2018. Commercial operations at the expanded production facilities are expected to commence in April 2019.
Liquid chromatography media are used in the production of biopharmaceuticals. Employing differences in charge, hydrophobicity, specific affinity, and molecular size, these media are designed to separate and purify target components. Given the rapid growth of the market for biopharmaceutical products, in Japan, the United States, countries in Europe and in China, India, and other emerging nations, these media are in high demand. And Tosoh is committed to meeting that demand.
With its high strength, superior chemical stability, and high adsorption capacity, TOYOPEARL ranks among Tosoh’s bioscience operation’s leading products. It is well suited to the industrial-scale purification processes used by pharmaceutical and other companies for target ingredients. Tosoh has seen particularly strong demand for TOYOPEARL’s antibody drug purification from the biopharmaceutical industry.
The company offers a complete lineup of resins as well as screening and pre-packed columns and an organization ready and able to meet each customer’s particular requirements. With the expansion of its TOYOPEARL production capacity, Tosoh will be better positioned to respond to vigorous demand in the market for separation and purification media. Tosoh plans further expansions of the scale and profitability of its business going forward.
WHO WE ARE
Tosoh is the parent of the Tosoh Group, which comprises over 100 companies worldwide and a multiethnic workforce of over 12,000 people and generated net sales of ¥ 753.7 billion (about 6.3 billion Euro) in fiscal 2016, ended March 31, 2016. In Europe, Middle East and Africa, TOYOPEARL resins are distributed by Tosoh Bioscience GmbH. Headquartered in Griesheim, Germany, Tosoh Bioscience offers extensive technical support like application development, on-site training and workshops.
WHAT WE DO
Tosoh is one of the largest chlor-alkali manufacturers in Asia. The company supplies the plastic resins and an array of the basic chemicals that support modern life. Tosoh’s petrochemical operations supply ethylene, polyethylene, and functional polymers, while its advanced materials business serves the global semiconductor, display, and solar industries. Tosoh has also pioneered sophisticated bioscience systems that are used for the monitoring of life-threatening diseases. In addition, Tosoh demonstrates its commitment to a sustainable future, in part by manufacturing a variety of eco-products.
Stock Exchange Ticker Symbol: JP: 4042
Contact: Regina Römling, Senior Marketing Manager Tosoh Bioscience GmbH; [email protected]